Human Papillomavirus (HPV) and Genital Warts

Human Papillomavirus (HPV) and Genital Warts

Shiken premium Upgrade Banner


Human papillomavirus (HPV) is a non-enveloped double-stranded circular DNA virus in the Papillomaviridae family. There are over 150 different types of HPV, with 40 affecting the anogenital area and 15 being oncogenic in nature.

Low-risk types of HPV, such as HPV-6 and HPV-11, are responsible for causing genital warts, which is the most common type of viral sexually transmitted infection (STI).

High-risk HPV types can lead to the formation of malignant tumors - worldwide, they are estimated to cause around 5% of all cancer cases, primarily in the cervix, vulva, vagina, anus, penis, head, and neck.


HPV is highly prevalent, with nearly all sexually active men and women being infected in their lifetime. Forty percent of women are estimated to acquire HPV infection within the first two years of sexual activity.

Genital warts, which are caused by low-risk HPV-6 and HPV-11, is the most common viral STI worldwide. In 2019, there were 50,700 diagnoses of the first episode of genital warts; however, this number decreased to 27,473 in 2020 - attributed to an expanded HPV vaccine programme and a reduction of face-to-face consultations during the COVID-19 pandemic.

In the UK, high-risk HPV is present in 16% of the population, with the most common type being HPV-16 (12%). High-risk HPV types can cause cancer through the mechanisms described below.

HPV Epidemiology

Human Papillomavirus (HPV) belongs to the Papillomaviridae family and includes over 200 different types which are grouped according to their genome. Although all HPV types can cause proliferative lesions, the most prevalent types are classified as high-risk or low-risk according to their risk of causing malignant neoplasms or benign lesions, such as genital warts.

Important high-risk types include HPV-16 and HPV-18, which contribute to over 70% of cervical cancer, and 31, 33, 35, 45, 52 and 58, which account for an additional 20% of cervical cancers. Low-risk HPV capable of causing genital warts include HPV-6 and HPV-11.

HPV Life Cycle

Microtrauma to the epithelial cells of the skin, oral and genital mucosa provides the virus access to basal keratinocytes. HPV utilizes its L1 and L2 capsid proteins to bind and enter the cell via endocytosis.

The undifferentiated basal layer acts as a reservoir, proliferating symmetrically to form more basal cells, wherein HPV establishes a persistent infection, or asymmetrically, whereby one daughter cell moves up through the epithelium. As these infected basal cells differentiate into epithelial cells, the virus begins expressing its early (E) genes, allowing it to replicate and produce new virions to be released from the differentiated epithelial cell surface.

The majority (70-90%) of HPV infections are asymptomatic and are cleared within 12-14 months by the immune system via a Th1 pro-inflammatory and cell-mediated response.

This immune response may be sufficient to completely clear the viral infection or to keep the virus in very low copy numbers which avoid detection. However, only 70-80% of genital HPV infection results in antibody production, which is insufficient to control for new infections.

Pathophysiology and Carcinogenesis

HPV employs several strategies to induce hyperproliferation of the infected epithelia, resulting in warts:

  • Genital warts: verrucous papules in the anogenital area
  • Common warts: rough, raised bumps commonly on the hands and fingers
  • Plantar warts (verrucas): hard, grainy growth commonly on the heels or balls of feet
  • Flat warts: flat-topped, raised lesions commonly on the face

High-risk HPV types can remain intraepithelial by proliferating through the undifferentiated layer of cells, thereby avoiding the host immune response. These oncogenic types demonstrate increased activity of viral E6 and E7 oncoproteins, which respectively inhibit p53 and pRb tumour suppressor genes. This results in cell cycle dysregulation, uncontrolled cellular proliferation and the accumulation of mutations that can lead to invasive malignancy.


HPV is transmitted primarily through direct skin-skin contact during sexual intercourse.

Other modes of transmission include contact with contaminated surfaces or objects, oro-genital contact, transmission from mother to child during birth, and autoinoculation.

Risk factors

Risk factors associated with HPV include early age of first sexual intercourse, having multiple sexual partners, having unprotected sex, and immunosuppression including HIV.

Clinical features


Most HPV infections (70-90%) are asymptomatic and are cleared by the immune system within 12-14 months. Warts tend to present as single or multiple cauliflower-like growths, which may be soft and non-keratinised on non-hairy skin or firm and keratinised on hairy skin. Symptoms may include itching and irritation, pain and bleeding, and urinary flow obstruction due to intra-meatal warts. A sexual history should be taken to assess relevant risk factors.

Clinical examination

The anogenital area, external genitalia, perineum, and anus should be examined to confirm the diagnosis and determine the extent of the lesions. Other examinations may include a vaginal speculum exam, meatoscopy, proctoscopy, and anoscopy in patients with recurrent perianal warts.

Differential diagnoses

Table 1. Differential diagnoses to consider in the context of anogenital lesions.

Differential diagnosisClinical summaryCondyloma latum

  • Moist whiteish papules which may secrete fluid
  • Highly contagious manifestation of secondary syphilis
  • Systemic symptoms may include fever, malaise, weight loss

Molluscum contagiosum

  • Fleshy or pearl-coloured lesions with central dells
  • Caused by the molluscum contagiosum virus (Poxvirus)

Pearly penile papules

  • 1-2mm flesh-coloured papules around the corona or sulcus of the penis glans
  • Asymptomatic, normal anatomical variant

Skin tags

  • Soft, skin-coloured or tan-brown, round/oval, pedunculated papilloma
  • Usually found on the neck, armpits, around the groin or under breasts

Carcinoma in situ

  • Multifocal, erythematous or pigmented lesions
  • Usually have a smooth and velvety surface


Genital warts are diagnosed following clinical examination. Swabs and blood tests are not routinely performed. However, it is important to offer a full sexual health screen.


At the bedside, diagnostic testing may include taking a urine sample and swabs from the vagina, cervix, rectum and oropharynx to screen for chlamydia and gonorrhoea. Other laboratory investigations may involve a full blood count, CRP and serology for HIV, syphilis, HBV and HCV.

Biopsy could be considered if the wart is indurated, fixed, bleeding, ulcerated or pigmented.


Although there is no specific treatment for HPV infection, treatments are available to destroy or remove warts and lesions. Self-administered treatment includes topical treatment with podophyllotoxin, imiquimod and sinecathins. Specialists may treat with trichloroacetic acid, or use ablative methods such as cryotherapy, excision or electrocautery.

Patient Advice

All patients should be advised to quit smoking and use barrier methods of contraception. Patients may also suggest that sexual partners may benefit from assessment for undetected genital warts and other STIs. Patients should also be reassured that a recent diagnosis does not always imply partner infidelity due to the long latency of HPV.


Protective factors against HPV infection include condom usage, male circumcision, limiting the number of sexual partners and vaccination.


HPV vaccines contain particles from the major protein of the viral capsid. Currently, the following groups are eligible:

  • Girls and boys aged 11-14: 2 doses, one given 6-24 months after the first
  • Individuals aged 15-25 who did not receive it: 2 doses, 6 months apart
  • Men-who-have-sex-with-men (MSM) aged 15-45: 2 doses, 6 months apart
  • High-risk individuals (transgender, sex workers): 2 doses, 6 months apart
  • People living with HIV (PLWH): 3 doses, all within 24 months

The bivalent vaccine against HPV 16 and 18 was introduced in the national immunisation programme in 2008, and this has since been replaced by the quadrivalent vaccine Gardasil (against HPV 6, 11, 16 and 18). This is planned to be replaced again in 2022 by the 9-valent vaccine Gardasil 9 (against HPV 6, 11, 16, 18, 31, 33, 45, 52 and 58) to offer more protection against cancer and genital warts. Vaccination programmes are aimed at both girls and boys aged 11-14, and other eligible groups. As of 2020, there is 85% coverage for girls and 53% for boys.


The main complications are caused by anxiety and distress relating to the appearance of warts. Side effects of topical treatments may include persistent hypo- or hyper-pigmentation and hypertrophic scarring.


In around 20% of people, warts disappear within 6 months, requiring no treatment.

Key points

  • Human papillomavirus (HPV) is a DNA virus that infects the basal epithelium of the skin and oral and genital mucosa
  • It is acquired by nearly all sexually active adults during their lifetime
  • HPV is transmitted primarily through sexual intercourse
  • Important risk factors include early sexual intercourse, a high number of sexual partners, condomless sex, HIV infection and immunosuppression
  • Most HPV infections are asymptomatic and cleared by the immune system within 2 years
  • High-risk HPV include HPV 16 and HPV 18, which can cause cancers such as cervical cancer
  • Low-risk HPV includes HPV 6 and HPV 11, which can cause genital warts
  • Genital warts can cause pruritus, bleeding, pain and urinary symptoms but may also be asymptomatic
  • In 20% of cases, warts will disappear within 6 months, but they can be treated with topical or ablative therapies
  • HPV can be prevented with vaccination, offered to certain demographics


  1. de Sanjose, S., Brotons, M. and Pavon, M.A., 2018. The natural history of human papillomavirus infection. Best practice & research Clinical obstetrics & gynaecology, 47, pp.2-13.
  2. Bruni L, Albero G, Serrano B, Mena M, Collado JJ, Gómez D, Muñoz J, Bosch FX, de Sanjosé S. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in United Kingdom of Great Britain and Northern Ireland. Summary Report 22 October 2021.
  3. Centre for Disease Control, 2022. HPV Available at [LINK]
  4. Public Health England, 2014. Human papillomavirus (HPV): the green book, chapter 18a.
  5. Public Health England, 2019. Sexually transmitted infections and screening for chlamydia in England. Health Protection Report, 13(19), pp.1-38.
  6. Sonnenberg, P., Tanton, C., Mesher, D., King, E., Beddows, S., Field, N., Mercer, C.H., Soldan, K. and Johnson, A.M., 2019. Epidemiology of genital warts in the British population: implications for HPV vaccination programmes. Sexually transmitted infections, 95(5), pp.386-390.
  7. Roden, R.B. and Stern, P.L., 2018. Opportunities and challenges for human papillomavirus vaccination in cancer. Nature Reviews Cancer, 18(4), pp.240-254.
  8. Mammas, I.N., Sourvinos, G. and Spandidos, D.A., 2009. Human papilloma virus (HPV) infection in children and adolescents. European journal of pediatrics, 168(3), pp.267-273.
  9. National Institute for Health and Care Excellence, 2017. Warts – anogenital. Available at [LINK]

Join Shiken For FREE

Gumbo Study Buddy

Explore More Subject Explanations

Try Shiken Premium
for Free

14-day free trial. Cancel anytime.
Get Started
Join 10,000+ learners worldwide.
The first 14 days are on us
96% of learners report x2 faster learning
Free hands-on onboarding & support
Cancel Anytime